Notes

Slide Show

Outline

1
2	Europe: Prevalence of HIV/HBV co-infection
3	Natural history of HBV infection – where does co-infection fit in?
4	Screening All HBsAg+ patients should be screened for Delta virus antibodies
5	Delta virus hepatitis Delta virus coinfection/superinfection in 5-15% of HIV/HBV co-infected Particularly in IVDUs, Eastern/Central/Southern Europe, sub-Saharan Africa Often low levels of HBV DNA or HCV RNA Often aggressive hepatic fibrosis
6	HIV/HBV co-infection: Natural history (MACS)
7	Chronic hepatitis B: Influence of HBV DNA
8	Agents for treatment of hepatitis B in HIV co-infection
9	Liver disease associated mortality in HIV: 1995–2003 GERMIVIC
10	Interferon treatment in HIV/HBV co-infected patients
11	Rates of undetectable HBV at one year of therapy in randomized clinical trials in patients with CHB monoinfection
12
13	Resistance development: HBV-polymerase inhibitors
14	TICO Study: TDF-containing HAART vs 3TC-containing HAART in ARV-naive HIV/HBV coinfected patients Randomized Thai trial (1:1:1) of 3TC vs TDF vs 3TC/TDF within a EFV-based HAART regimen (n=36) Hepatic flare in 9 (25%) patients, 4 of whom had HBe-Ag loss (2 with HBsAg seroconversion) 1 died of hepatic decompensation Detectable HBV viremia at Week 48 is a risk factor for future HBV resistance development (2 cases of 3TC resistance in 3TC only group) Good initial anti-HBV response for all 3 arms but more resistance in the 3TC arm at wk 48
15	Tenofovir vs. Tenofovir + Lamivudin (HBV/HIV-coinfection)
16	Anti-HIV activity of entecavir
17	Anti-HIV activity under telbivudine?
18	Initial in vitro studies on anti-HIV activity of telbivudine and entecavir in two HIV isolates
19	Treatment of chronic HBV infection in HIV-positive individuals
20	News in hepatitis B
21	Rapid rebound in HBV DNA in previously undetectable hepatitis B/HIV co-infected patients switching from tenofovir to entecavir therapy
22	Summary Chronic hepatitis B can be found in up to 8% of all HIV-patients HBV/HIV coinfected patients show a faster progression to cirrhosis and increased liver-related mortality Do not forget to check for HDV superinfection ARV in HIV/HBV co-infected patients should include TDF and 3TC or FTC In patients with no HAART indication (>500/µl) early HAART still remains an option; alternatives are PEG-IFN, or de novo adefovir/telbivudine therapy
23	Prevalence of hepatitis C in the HIV population (1960/5957 patients = 33%)
24	Hepatitis C co-infection in EuroSIDA
25	Progression to cirrhosis
26	PRESCO trial: design
27	Ribavirin dose in Genotype 1: EVR APRICOT (800 mg) vs PRESCO (1000–1200 mg)
28	ETR response and SVR rates in PRESCO
29	SVR rates in the PRESCO trial
30	Proposed optimal duration of HCV therapy in HCV/HIV co-infected patients
31	Ribavirin in HIV/HCV co-infection
32	Negative impact of abacavir on SVR
33	NUC-free HAART may improve SVR German multicentre study
34	Rate of SVR increases with higher CD4% at baseline: APRICOT
35	Summary Chronic hepatitis C can be found in 30% of all HIV-patients HCV/HIV coinfected patients show a faster progression to cirrhosis and increased liver-related mortality With availability of pegylated interferon Hepatitis C specific treatment options should be considered before onset of immunodeficiency in HIV-coinfected patients HAART should not be withheld in coinfected patients